Although the lack of mechanistic studies makes it unclear as to how meningiomas are dependent on HDAC activity, the suppressed growth observed in our in vitro cohort as well as these two in vivo studies [38,39] supports the therapeutic potential of HDAC inhibitors for the treatment of meningioma. Here, HDAC9 is linked to meningioma.